Mindset Pharma Files International Patent Application Covering Its ‘Family 3’ Microdose Psychedelic Compounds
Mindset Pharma Inc. (Mindset), a drug discovery and development company focused on creating optimized and patentable next-generation microdose psychedelic medicines to treat neurological and psychiatric disorders with unmet medical needs, filed an international patent application covering its Family 3 novel psychedelic compounds. Mindset’s Family 3 consists of certain compounds that have demonstrated half-lives extending well beyond those exhibited by comparable classical psychedelic drugs with no significant reduction in binding affinity at the serotonin 5-HT2A receptor.
Mindset was established to develop next generation pharmaceutical assets that leverage the breakthrough therapeutic potential of psychedelic drugs. Mindset is developing . . .
